Pharmaceuticals, Biotechnology and Life Sciences
-Four-Year Update of the ECHELON-1 Trial Continues to Support Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared…
– Results Demonstrated Statistically Significant Improvement in Progression-Free Survival – – Data to be Submitted for Presentation at an Upcoming…
$37.6M in Rubraca® (rucaparib) net product revenue for Q3 2019, up 65% year over year Net product revenue increased 14%…
DUBLIN–(BUSINESS WIRE)–The “Unituxin- Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. “Unituxin Drug Insight, 2019” highlights the drug…
Results of MIRA-1 and ORION-1 Phase 2b Studies Confirm Drug Product Profile and Provide Basis for Additional Patent Claims Nyxol…
Crescita had total revenue, consisting of product sales, out-licensing and services revenue, was $4,906 for the three months ended September 30, 2019, compared to $4,464 for the three months ended September 30, 2018.
Data to be shared during oral podium presentation at SITC 2019 Durable clinical benefit seen in multiple patients Abscopal responses…
HLS Therapeutics posted $1.9 million net loss in the third quarter 2019, compared to the same period last year, when it was compared to net loss of $19.7 million, boosted by Canadian-based clozaril sales in the last day of Q2.
DUBLIN–(BUSINESS WIRE)–The “Dermatitis Drugs Global Market Report 2020” report has been added to ResearchAndMarkets.com’s offering. Where is the largest and…
TRUXIMA Available Week of November 11 JERUSALEM & PARSIPPANY, N.J. & INCHEON, South Korea–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a U.S.…